High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.

Arun Azad, Fiona Chionh, Andrew M. Scott, Szeting T. Lee, Sam U. Berlangieri, Shane White, Paul L. Mitchell

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)

Abstract

PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26%) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26%) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.

Original languageEnglish
Pages (from-to)443-451
Number of pages9
JournalMolecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Volume12
Issue number4
DOIs
Publication statusPublished - Aug 2010

Cite this

@article{03d1b0c4679a411faa5c1b4dee5cf5a5,
title = "High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.",
abstract = "PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26{\%}) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26{\%}) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.",
author = "Arun Azad and Fiona Chionh and Scott, {Andrew M.} and Lee, {Szeting T.} and Berlangieri, {Sam U.} and Shane White and Mitchell, {Paul L.}",
year = "2010",
month = "8",
doi = "10.1007/s11307-009-0295-z",
language = "English",
volume = "12",
pages = "443--451",
journal = "Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging",
issn = "1536-1632",
publisher = "Springer-Verlag London Ltd.",
number = "4",

}

High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. / Azad, Arun; Chionh, Fiona; Scott, Andrew M.; Lee, Szeting T.; Berlangieri, Sam U.; White, Shane; Mitchell, Paul L.

In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, Vol. 12, No. 4, 08.2010, p. 443-451.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.

AU - Azad, Arun

AU - Chionh, Fiona

AU - Scott, Andrew M.

AU - Lee, Szeting T.

AU - Berlangieri, Sam U.

AU - White, Shane

AU - Mitchell, Paul L.

PY - 2010/8

Y1 - 2010/8

N2 - PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26%) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26%) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.

AB - PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26%) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26%) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.

UR - http://www.scopus.com/inward/record.url?scp=78149277688&partnerID=8YFLogxK

U2 - 10.1007/s11307-009-0295-z

DO - 10.1007/s11307-009-0295-z

M3 - Article

C2 - 19921339

AN - SCOPUS:78149277688

VL - 12

SP - 443

EP - 451

JO - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging

JF - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging

SN - 1536-1632

IS - 4

ER -